Shares of Arch Therapeutics Inc (NASDAQ:ARTH) have been assigned an average recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $2.83.

A number of equities analysts recently issued reports on the stock. ValuEngine raised shares of Arch Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Zacks Investment Research downgraded shares of Arch Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of Arch Therapeutics in a research note on Monday, September 18th. Finally, Ifs Securities reissued an “outperform” rating on shares of Arch Therapeutics in a research note on Tuesday, July 25th.

Arch Therapeutics (NASDAQ ARTH) opened at $0.72 on Friday. Arch Therapeutics has a one year low of $0.41 and a one year high of $0.89.

TRADEMARK VIOLATION WARNING: “Arch Therapeutics Inc (ARTH) Receives Consensus Rating of “Buy” from Brokerages” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/05/arch-therapeutics-inc-arth-receives-consensus-rating-of-buy-from-brokerages.html.

Arch Therapeutics Company Profile

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Receive News & Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.